Migraine Response in Patients with Migraine Receiving Eptinezumab Treatment: Consistency Throughout the PROMISE-1 and PROMISE-2 Trials

Stephen D. Silberstein, MD

AHSAM 2020 - Poster session
Published on July 17, 2020

1 minute listen
1 minute read

Key messages

  • Sustained efficacy was seen in over half of patients experiencing migraine response during Month 1 continuing to respond to Month 6.
  • Approximately one-third of eptinezumab- treated patients were ≥50% migraine responders and 10.7–14.3% were ≥75% migraine responders for all 6 study months compared to 19.7% and 6.0% for placebo.
  • For patients not experiencing migraine response during Month 1, most were likely to experience ≥1 study month of migraine response during the remainder of the study.
  • Podcast by Stephen D. Silberstein, MD

Key messages

  • Sustained efficacy was seen in over half of patients experiencing migraine response during Month 1 continuing to respond to Month 6.
  • Approximately one-third of eptinezumab- treated patients were ≥50% migraine responders and 10.7–14.3% were ≥75% migraine responders for all 6 study months compared to 19.7% and 6.0% for placebo.
  • For patients not experiencing migraine response during Month 1, most were likely to experience ≥1 study month of migraine response during the remainder of the study.

Podcast by Stephen D. Silberstein, MD

Stephen D. Silberstein, MD
Director
Jefferson Headache Center
Philadelphia, Pennsylvania

 

Dr. Silberstein is Professor of Neurology and Director of the Jefferson Headache Center at Thomas Jefferson University. He is a Fellow of the American College of Physicians, the American Academy of Neurology, and the American Headache Society. He has served the American Headache Society as President, Treasurer, and Board of Directors member, as well as on the Publications, Scientific, and Education Committees, and was Co-Chairman of the Annual Scientific Meeting. In 2016, he was awarded a Lifetime Achievement Award by the American Headache Society. He is an active member of the American Academy of Neurology and was Co-Director of the national and international Headache Guideline Project. He was the chairman of the International Headache Society meeting in Philadelphia in 2009. He is chairman of the headache research group of the World Federation of Neurology and President of the Philadelphia Headache Society. 
Dr. Silberstein is the senior editor of the 8th edition of Wolff’s Headache and Other Head Pain, Associate Editor of Cephalalgia and CNS Drugs, and a present or prior member of the Editorial Board of Headache, Cephalalgia, Acta Neurologica Scandanavia, Journal of Neurology, Neurosurgery and Psychology, and Topics in Pain Management. He is an ad hoc reviewer for many publications, with >300 peer-reviewed publications to his credit. 
Dr. Silberstein received his medical degree from the University of Pennsylvania. He did a medical internship at the Hospital of the University of Pennsylvania. After completing a fellowship in neurology at the National Hospital for Nervous Diseases in London, he completed a medicine/neurology residency at the Hospital of the University of Pennsylvania. He served as a pharmacology research associate in the Toxicology Laboratory of Clinical Science at the National Institutes of Mental Health and completed a neurology residency at the Hospital of the University of Pennsylvania. 

Stephen D. Silberstein, MD: Alder Biopharmaceuticals (Other Activities) (Honoraria, Other Financial or Material Support, is a consultant and/or advisory panel member for and has received honoraria from)Allergan (Other Activities) (Honoraria, Other Financial or Material Support, Research Grant or Support, is a consultant and/or advisory panel member for and has received honoraria from) Amgen (Other Activities) (Honoraria, Other Financial or Material Support, Research Grant or Support, is a consultant and/or advisory panel member for and has received honoraria from) Avanir (Other Activities) (Honoraria, Other Financial or Material Support, is a consultant and/or advisory panel member for and has received honoraria from) ElectroCore Medical (Other Activities) (Honoraria, Other Financial or Material Support, Research Grant or Support, is a consultant and/or advisory panel member for and has received honoraria from) Eli Lilly (Other Activities) (Research Grant or Support)eNeura(Other Activities) (Honoraria, Other Financial or Material Support, is a consultant and/or advisory panel member for and has received honoraria from) Labrys Biologics (Other Activities) (Honoraria, Other Financial or Material Support, Research Grant or Support, is a consultant and/or advisory panel member for and has received honoraria from) Mars (Other Activities) (Research Grant or Support) Medscape (Other Activities) (Honoraria, Other Financial or Material Support, is a consultant and/or advisory panel member for and has received honoraria from) Medtronic (Other Activities) (Honoraria, Other Financial or Material Support, is a consultant and/or advisory panel member for and has received honoraria from) Neuralieve (Other Activities) (Honoraria, Other Financial or Material Support, is a consultant and/or advisory panel member for and has received honoraria from) NINDS(Other Activities) (Honoraria, Other Financial or Material Support, is a consultant and/or advisory panel member for and has received honoraria from)Pfizer (Other Activities) (Honoraria, Other Financial or Material Support, is a consultant and/or advisory panel member for and has received honoraria from) Teva (Other Activities) (Honoraria, Other Financial or Material Support, is a consultant and/or advisory panel member for and has received honoraria from) Troy Healthcare (Other Activities) (Research Grant or Support)



Headache
Migraine


Scan to open on your mobile device